biotech

Bio-Analyst

Research Platform
person
arrow_backExplore/Inositol
Tier-BPublic-ready7/2/2026

Inositol

Glucose and metabolic health markers is closer to a research marker, so it should be read separately from a directly felt benefit.

The 56.0 score includes research signals from patient or disease contexts. General supplement evidence is not repeated enough, so the B tier remains conservative.

Representative tier calculated from paper evidence that passed the collection audit.

Papers analyzed
88
Caution signal
Low
Context-specific research signal
56.0
Glucose and metabolic health markersMenstrual and women's healthCholesterol and triglycerides

Main benefit evidence

The representative ingredient tier is calculated from these target-level evidence groups.

Glucose and metabolic health
6 studiesTier-B
Glucose and metabolic health markers
Fairly consistent positive signal in studiesResearch marker focusPatient-group study

This card is closer to a measured biomarker or lab outcome than a directly felt user benefit. These findings come from a defined study population, so everyday effects may differ.

Evidence score
58.5
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Women's health
5 studiesTier-B
Menstrual and women's health
Fairly consistent positive signal in studiesFelt benefit focusPatient-group study

Potential benefit studied in Women's health. These findings come from a defined study population, so everyday effects may differ.

Evidence score
56.7
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Blood lipids
3 studiesTier-B
Cholesterol and triglycerides
Fairly consistent positive signal in studiesFelt benefit focusPatient-group study

Potential benefit studied in Blood lipids. These findings come from a defined study population, so everyday effects may differ.

Evidence score
52.0
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Men's health
2 studiesTier-C
Male Reproductive Health Markers
Fairly consistent positive signal in studiesResearch marker focusPatient-group study

These findings come from sperm, semen, or hormone markers such as testosterone, LH, FSH, and inhibin B. They are closer to research measurements than a directly felt benefit. These findings come from a defined study population, so everyday effects may differ.

Evidence score
48.7
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Exercise performance and recovery
1 studiesTier-C
Exercise performance and recovery
Some positive signal observedFelt benefit focusPatient-group study

Potential benefit studied in Exercise performance and recovery. These findings come from a defined study population, so everyday effects may differ.

Evidence score
44.0
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Cognition and focus
1 studiesTier-C
Cognition, memory, and focus
Some positive signal observedFelt benefit focusPatient-group study

Potential benefit studied in Cognition and focus. These findings come from a defined study population, so everyday effects may differ.

Evidence score
20.9
Study context
Patient-group study

This score reflects the strength of this benefit group. The ingredient tier also considers paper count, repetition, population, and study context.

Recent research

Updated This Month10 new papers

Observed range in repeated studies

This range includes studies in specific patient groups. It is not a general dose or recommendation.

Lower observed study value
250
mg/day
Higher observed study value
3000
mg/day
Only ranges repeated in human, oral, single-ingredient studies are shown.
Not personal dosing instructions, recommendations, or safety limits.

Side effects and combination findings in studies

Findings from studies of this ingredient alone are separated from findings involving another supplement or medication.

Caution index
0.8
Caution band: Low
Caution signals
1
Side effects + combos + curated rules
Key precautions
No curated contraindication rule is available yet, but literature caution signals are shown below.
1 combo signals and 0 added-signal combos shown below.
These are signals reported in studies. They do not predict what will happen to an individual.

Findings to review with care

Side effects reported for the ingredient alone are separated from findings involving another supplement or medication.

Side effects reported when this ingredient was used alone

Symptoms or adverse events reported in studies of this ingredient without another active ingredient.

gastrointestinal adverse events1 papers
Myo-inositol likely causes fewer gastrointestinal adverse events compared with metformin, but these are typically mild and self-limited.Human studies · Meta-analysis

Positive combinations studied

Positive combination findings are separated by how the study compared the groups. This is not a recommendation to combine them.

Positive findings when used together

The combination had a positive result, but the contribution of each ingredient could not be separated.

SeleniumCombined administration of myo-inositol and selenium significantly decreased TSH, TPOAb, and TgAb levels and enhanced thyroid hormones compared to baseline.

Evidence summaries

Paper IDs and full lists are private. Only study types and summaries are shown.

Key Evidence #1
Public scholarly dataCitation signal: 273
observational

[Abstract]: In this review we discuss the biological significance of D-chiro-inositol, originally discovered as a component of a putative mediator of intracellular insulin action, where as a putative mediator, it accelerates the dephosphorylation of glycogen s

Key Evidence #2
Public scholarly dataCitation signal: 199
observational

[Abstract]: Major depressive disorder (MDD) is a serious mental illness, characterized by high morbidity, which has increased in recent decades. However, the molecular mechanisms underlying MDD remain unclear. Previous studies have identified altered metabolic

Key Evidence #3
Public scholarly dataCitation signal: 167
observational

[Abstract]: OBJECTIVE To check the hypothesis that myo-inositol supplementation may reduce gestational diabetes mellitus (GDM) onset in pregnant women with a family history of type 2 diabetes. RESEARCH DESIGN AND METHODS A 2-year, prospective, randomized, open

3 more summariesLimited representative sample by study type.
>
Public scholarly dataCitation signal: 133
observational

This systematic review is the analysis of recent randomized clinical trials of inositol(s) in PCOS, in particular myo- and D-chiro-inositol, in order to better elucidate their physiological involvement inPCOS and potential therapeutic use, alone and in conjunc

Public scholarly dataCitation signal: 131
review

Given their functions, inositols are an attractive treatment option for PCOS, although well-designed studies on spontaneous and non-spontaneous fertility are needed.

Public scholarly dataCitation signal: 128
observational

The trial sequential analysis of insulin meta-analysis illustrates that the cumulative z-curve crossed the monitoring boundary, providing firm evidence of the intervention effect of MI in improving the metabolic profile of women with PCOS, concomitantly reduci

Inositol
arrow_backBack to list